Sanofi
Search results
Boehringer Ingelheim is a research-driven group of companies dedicated to the discovery, development, manufacture and marketing of innovative health care products. Section Overview
Boehringer Ingelheim is a global group of companies embracing many cultures and diverse societies. Learn more about the financial highlights, the corporate vision and the organisation. View this Section
C.H. Boehringer Sohn AG & Co. KG is the parent company of the Boehringer Ingelheim group, which was founded in 1885 by Albert Boehringer (1861–1939) in Ingelheim am Rhein, Germany. As of 2018, Boehringer Ingelheim is one of the world's largest pharmaceutical companies, and the largest private one.
Boehringer Ingelheim. We have been transforming lives in healthcare since 1885. Our 53,500 employees in 130 markets create value through innovation by infusing long-term, sustainable thinking into our Human Pharma and Animal Health units.
See our extensive range of human pharmaceutical and animal health products, see how our medicals products are improving patient lives human or animal.
Boehringer Ingelheim | Annual Report 2022. Innovation drives us at Boehringer Ingelheim as we strive to positively impact lives of humans and animals with our innovative solutions. In 2022 we were able to help more people than ever before.
Schizophrenia is complex and stigmatized, demanding comprehensive understanding and care. Boehringer Ingelheim's commitment could revolutionize treatment, improving mental health and transforming lives. Visit story →
Boehringer Ingelheim has over 90 years of heritage in managing respiratory disease. Since 1921 we have emerged as a leader in this disease area, having launched several treatments in a range of respiratory conditions including asthma, chronic obstructive pulmonary disease (COPD), idiopathic pulmonary fibrosis (IPF) and lung cancer.
Apr 16, 2024 · Boehringer Ingelheim As one of the industry’s top investors in Research and Development, the company focuses on developing innovative therapies in areas of high unmet medical need.
Boehringer Ingelheim makes fundamental progress in research and development . In the first half of 2022, Boehringer Ingelheim continued to improve the supply of medicines to patients and expanded its research pipeline in an increasingly difficult economic, political and regulatory environment.
